The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 03, 2016
Filed:
Feb. 09, 2012
Leonard D. Kohn, Athens, OH (US);
Norikazu Harii, Yaminashi, JP;
Uruguaysito Benavides-peralta, Montevideo, UY;
Mariana Gonzalez-murguiondo, Montevideo, UY;
Christopher J. Lewis, Athens, OH (US);
Douglas J. Goetz, Athens, OH (US);
Giorgio Napolitano, Athens, OH (US);
Cesidio Giuliani, Athens, OH (US);
Ramiro Malgor, Athens, OH (US);
Frank Schwartz, Vienna, WV (US);
Kelly D. Mccall, Athens, OH (US);
Leonard D. Kohn, Athens, OH (US);
Norikazu Harii, Yaminashi, JP;
Uruguaysito Benavides-Peralta, Montevideo, UY;
Mariana Gonzalez-Murguiondo, Montevideo, UY;
Christopher J. Lewis, Athens, OH (US);
Douglas J. Goetz, Athens, OH (US);
Giorgio Napolitano, Athens, OH (US);
Cesidio Giuliani, Athens, OH (US);
Ramiro Malgor, Athens, OH (US);
Frank Schwartz, Vienna, WV (US);
Kelly D. McCall, Athens, OH (US);
Ohio University, Athens, OH (US);
Abstract
Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.